Atea Pharmaceuticals, Inc.

NasdaqGS:AVIR Stock Report

Mkt Cap: US$383.1m

Atea Pharmaceuticals Future Growth

How is Atea Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-8.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:AVIR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202578-219N/AN/A1
12/31/2024230-1191011163
12/31/2023N/A-226-257-2403
9/30/202219236-177-175N/A
6/30/202222516-133-131N/A
3/31/202228548-129-129N/A
12/31/2021351121-87-87N/A
9/30/202120825307307N/A
6/30/202117535275275N/A
3/31/202111524284284N/A
12/31/202049-11297297N/A
9/30/2020N/A-36-26-26N/A
6/30/2020N/A-22-20-20N/A
3/31/2020N/A-16-14-14N/A
12/31/2019N/A-14-13-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVIR's earnings are forecast to decline over the next 3 years (-8.3% per year).

Earnings vs Market: AVIR's earnings are forecast to decline over the next 3 years (-8.3% per year).

High Growth Earnings: AVIR's earnings are forecast to decline over the next 3 years.

Revenue vs Market: AVIR is forecast to have no revenue next year.

High Growth Revenue: AVIR is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AVIR is forecast to be unprofitable in 3 years.


Discover growth companies